The Simplify Propel Opportunities ETF (SURI) seeks to provide long-term growth of capital by providing investors with exposure to biotech, pharma, health care technology, and life science companies that are believed to be overlooked by investors, thereby presenting significant opportunities for capital appreciation. The fund is sub-advised by Propel, which uses its deep scientific and commercial expertise in health sciences to identify the most promising health science investment opportunities.
Simplify Propel Opportunities ETF · Issued by Simplify
| PAGP | Plains GP Holdings LP Class A | 41.33% |
| ACHV | Achieve Life Sciences Inc | 13.09% |
| DCTH | Delcath Systems Inc | 4.58% |
| MIST | Milestone Pharmaceuticals Inc | 4.47% |
| CORT | Corcept Therapeutics Inc | 3.06% |
| PHAT | Phathom Pharmaceuticals Inc Ordinary shares | 2.75% |
| COLL | Collegium Pharmaceutical Inc | 2.29% |
| ABEO | Abeona Therapeutics Inc | 1.86% |
| KYTX | Kyverna Therapeutics Inc | 1.78% |
No recent news for SURI. The ingest cron pulls every 15 minutes during market hours.